Hassan R - Search Results

1

CA125 suppresses amatuximab immune-effector function and elevated serum levels are associated with reduced clinical response in first line mesothelioma patients.

Nicolaides NC, Schweizer C, Somers EB, Wang W, Fernando S, Ross EN, Grasso L, Hassan R, Kline JB. Nicolaides NC, et al. Among authors: hassan r. Cancer Biol Ther. 2018 Jul 3;19(7):622-630. doi: 10.1080/15384047.2018.1449614. Epub 2018 Apr 25. Cancer Biol Ther. 2018. PMID: 29652548 Free PMC article.

2

Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients.

Ho M, Hassan R, Zhang J, Wang QC, Onda M, Bera T, Pastan I. Ho M, et al. Among authors: hassan r. Clin Cancer Res. 2005 May 15;11(10):3814-20. doi: 10.1158/1078-0432.CCR-04-2304. Clin Cancer Res. 2005. PMID: 15897581

3

Megakaryocyte potentiation factor cleaved from mesothelin precursor is a useful tumor marker in the serum of patients with mesothelioma.

Onda M, Nagata S, Ho M, Bera TK, Hassan R, Alexander RH, Pastan I. Onda M, et al. Among authors: hassan r. Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4225-31. doi: 10.1158/1078-0432.CCR-06-0472. Clin Cancer Res. 2006. PMID: 16857795

4

Mesothelin targeted cancer immunotherapy.

Hassan R, Ho M. Hassan R, et al. Eur J Cancer. 2008 Jan;44(1):46-53. doi: 10.1016/j.ejca.2007.08.028. Epub 2007 Oct 22. Eur J Cancer. 2008. PMID: 17945478 Free PMC article. Review.

5

Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin.

Hassan R, Ebel W, Routhier EL, Patel R, Kline JB, Zhang J, Chao Q, Jacob S, Turchin H, Gibbs L, Phillips MD, Mudali S, Iacobuzio-Donahue C, Jaffee EM, Moreno M, Pastan I, Sass PM, Nicolaides NC, Grasso L. Hassan R, et al. Cancer Immun. 2007 Dec 19;7:20. Cancer Immun. 2007. PMID: 18088084 Free PMC article.

6

A binding domain on mesothelin for CA125/MUC16.

Kaneko O, Gong L, Zhang J, Hansen JK, Hassan R, Lee B, Ho M. Kaneko O, et al. Among authors: hassan r. J Biol Chem. 2009 Feb 6;284(6):3739-49. doi: 10.1074/jbc.M806776200. Epub 2008 Dec 15. J Biol Chem. 2009. PMID: 19075018 Free PMC article.

7

Inhibition of mesothelin-CA-125 interaction in patients with mesothelioma by the anti-mesothelin monoclonal antibody MORAb-009: Implications for cancer therapy.

Hassan R, Schweizer C, Lu KF, Schuler B, Remaley AT, Weil SC, Pastan I. Hassan R, et al. Lung Cancer. 2010 Jun;68(3):455-9. doi: 10.1016/j.lungcan.2009.07.016. Epub 2009 Sep 9. Lung Cancer. 2010. PMID: 19744744 Free PMC article. Clinical Trial.

8

A flow cytometry method to quantitate internalized immunotoxins shows that taxol synergistically increases cellular immunotoxins uptake.

Zhang Y, Hansen JK, Xiang L, Kawa S, Onda M, Ho M, Hassan R, Pastan I. Zhang Y, et al. Among authors: hassan r. Cancer Res. 2010 Feb 1;70(3):1082-9. doi: 10.1158/0008-5472.CAN-09-2405. Epub 2010 Jan 26. Cancer Res. 2010. PMID: 20103626 Free PMC article.

9

Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers.

Hassan R, Cohen SJ, Phillips M, Pastan I, Sharon E, Kelly RJ, Schweizer C, Weil S, Laheru D. Hassan R, et al. Clin Cancer Res. 2010 Dec 15;16(24):6132-8. doi: 10.1158/1078-0432.CCR-10-2275. Epub 2010 Oct 29. Clin Cancer Res. 2010. PMID: 21037025 Free PMC article. Clinical Trial.

10

Chemotherapy and targeted therapies for unresectable malignant mesothelioma.

Kelly RJ, Sharon E, Hassan R. Kelly RJ, et al. Among authors: hassan r. Lung Cancer. 2011 Sep;73(3):256-63. doi: 10.1016/j.lungcan.2011.04.014. Epub 2011 May 28. Lung Cancer. 2011. PMID: 21620512 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,104 results

Search Page